-
July 22, 2022 A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 TrialCompass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new...
-
May 2, 2022 Elon Musk Excites Psychedelic Industry CEOs with This TweetThis is one of the billionaire's most explicit acknowledgments of the power of psychedelics for...
-
March 30, 2022 5 Most Important Psychedelic Clinical Trials in 2022Here's why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic...
-
January 12, 2022 Ketamine Trial for Alcohol Use Disorder Delivers Very Promising ResultsAwakn Life Sciences' Head of Ketamine-Assisted Therapy, Professor Celia Morgan, says world’s first controlled trial...
-
January 7, 2022 Psychedelic Business Spotlight — January 7This week in psychedelic business news: Mindset Pharma partners with global pharmaceutical company; Awakn Life...
-
November 19, 2021 Psychedelic Business Spotlight: November 19This week in psychedelic business news: Companies partner on new dosage method; MindMed investigates LSD...
-
October 29, 2021 Psychedelic Business Spotlight: October 29This week in psychedelic business news: MindMed's MDMA research pipeline to treat Autism Spectrum Disorder;...
-
September 17, 2021 Psychedelic Business Spotlight: September 17, 2021This week in psychedelic business news: Wesana teams up with MAPS, MindBio Therapeutics announces world-class...
-
July 13, 2021 Awakn Life Sciences CEO Details ‘Groundbreaking’ MDMA Discovery in Quest to Treat AddictionAnthony Tennyson tells the Psychedelic Spotlight Podcast that his company has "discovered receptor sites that...
-
March 16, 2021 U.K. Psychedelic R&D Company Investigates MDMA, Ketamine for AddictionAwakn Life Sciences is looking at psychedelics for addiction, namely MDMA and ketamine for alcohol...
